New research indicates that patients who discontinue blockbuster weight-loss injections like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who stop traditional diet and exercise regimens.
Published data in a leading health publication shows that while obese individuals frequently drop substantial amounts of their total mass while on the medication, the mass returns at an average rate of 0.8 kg per month once they quit.
"Individuals using such medications should be cognizant of the risk of quick rebound weight gain when the treatment is stopped," cautioned expert Dr. Susan Jebb.
Such speed of regain suggests a return to starting mass in about 18 months.
Weighing Treatments
The research, which looked at 37 of studies involving thousands of patients, contrasted the results of GLP-1 agonists with older methods.
The team point out that people who lose weight through dieting typically have a less rapid weight regain—perhaps 100 grams monthly—post-intervention.
The Reason for the Rapid Rebound
Doctors suggest the way of the injections explains the heightened rebound.
The injections imitate a body's own chemical called GLP-1, which controls appetite.
"Artificially providing the hormone levels far above than normal could lead to the body to produce less of its own natural hormone, and could diminish responsiveness to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this hormone supplement results in hunger is unsuppressed, making excessive eating far more likely."
An Ongoing Disease?
Medical guidelines suggest the jabs for people with obesity-related health risks, alongside prescribed lifestyle changes.
Professionals argue that, considering the significant potential of weight regain, the treatment is often long-term.
This opinion is supported by pharmaceutical companies, who state that the results "highlight the persistent nature of obesity," comparing it to managing conditions like hypertension.
Patient Accounts
People who have discontinued the medication report a sudden resurgence of appetite.
"I experienced a trigger activating and you become extremely hungry," described an individual.
The struggle is exacerbated if patients have not adopted permanent dietary or behavioural modifications during therapy.
Growing Adoption
Recent estimates show that a significant number of people in the UK have used these injections in the past year, with demand continuing to grow.
- Adoption is greater among females compared to males.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion access the drugs through private healthcare rather than public health services.
In conclusion, clinicians emphasize that while GLP-1 drugs are potent agents for weight loss, they are not a standalone solution and long-term success hinges on ongoing behavioural management.
